October 9, 2013
Chugai Pharmaceutical filed a new drug application (NDA) with Japan’s health ministry on October 7 for its anaplastic lymphoma kinase (ALK) inhibitor alectinib HCl for the treatment of ALK fusion gene positive non-small cell lung cancer (NSCLC). The company submitted...read more